INmune Bio has a remarkable technology platform
Three products ready to enter clinical trials
Good day everyone,
Today we are continuing our coverage on INmune Bio Inc. (NASDAQ: INMB), a clinical stage biotechnology company that is developing new immunotherapies to empower the body’s innate immune system to target and fight back against some of the world’s most debilitating conditions.
We are going to continue our coverage of INmune Bio with a longer-term view. INMB is a newer public company (February 2019) with a unique and impressive technological platform. Their approach to treatment for disease is highly technical and involves medicine at the cellular level.
The INMB platform proposes to change our body’s natural immune system to fight disease. The company is initially targeting Alzheimer’s and oncology indications, but the implications and possibilities of this technological approach to fighting disease are frankly mind boggling and warrant a longer-term view of the company’s value.
INMB is currently making presentations at several medical conferences across America. As the medical community gets indoctrinated to the company’s treatment platform and the data from their studies, we expect the interest in INMB could grow rapidly.
INmune Bio has a market value under $100 million. For a company with three different product candidates under consideration and the potential to revolutionize medicine, that figure may be low.
Yesterday we posed the question “Do you think INMB could be a potential acquisition target for big pharma?” We don’t know the answer to that question, but we know what big pharma looks for in acquisitions.
Simply put, market potential.
The INmune market potential:
INMB is developing XPro1595 for the Alzheimer’s/dementia market. There are 5.8 million Americans living with Alzheimer’s Disease and other dementias at a cost to the healthcare system of $290 billion dollars. Within 30 years, that figure is estimated to grow to $1.1 trillion dollars as the number of patients rises to 14 million.
Alzheimer’s is the 6th leading cause of death in the United States and 16 million people are providing uncompensated care for those afflicted. The current value of the uncompensated care (usually family members) is $234 billion.
INMB is developing INKmune for the cancer residual disease market. 2018 estimates indicated 1,735,350 new cancer cases and that 609,640 people will die from cancer. Estimated national expenditures for cancer care in the United States in 2017 were $147.3 billion. In future years, costs are likely to increase as the population ages and cancer prevalence increases. In fact, the number of new cancer cases per year is expected to rise to 23.6 million by 2030 by the National Cancer Institute.
The company’s initial research is on relapse / minimal residual disease in ovarian cancer. If the NCI is right and the number of new cancer cases rises to 23.6 million, the cost of cancer care will rise into the trillions of dollars.
INMB is developing INB03 for the resistance to cancer treatments market. The current monotherapy with Checkpoint Inhibitors (CPI) is effective in only one of four patients. Combining CPI with other therapies (like INB03) may improve the outcome in patients unresponsive to monotherapy. The CPI 2025 estimated market size $56 billion. INB03 in combination with CPI’s should increase the number of patients sensitive to CPIs. Initial targets will be melanoma and renal cell cancer.
INmune Bio is tackling some of the biggest markets in the medical field, with a unique platform, as well as working toward saving and improving lives. If the market projections are accurate, INMB could be involved, ultimately, in a multi-trillion dollar industry.
We want to remind you of a few facts from our letter yesterday (the entire text is available below too)
Many potential catalysts ahead:
All three of the candidates in the company’s pipeline are either currently in Phase 1 clinical studies or are about to begin Phase 1 clinical studies in the near term.
INB03 Australia Solid Tumors Initial Phase 1 Data Readout Q3 ’19
INKmune UK Ovarian Cancer Initiate Enrollment of Phase 1/2 study Q4 ’19
INB03 Australia Solid Tumors Initiate Combination Study, Additional Cohorts to Phase 1 Study 1H ’20
XPro1595 UK Alzheimer’s Initiate Enrollment of Phase 1 Study Q3’19
INKmune UK Ovarian Cancer Report Initial Phase 1 Data 1H ’20
XPro1595 UK Alzheimer’s Early Data Q1’20
INKmune UK Ovarian Cancer Initiate Phase 2 Study 2H ’20
INB03 Australia/US Solid Tumors Initiate INB03 + CPI* Phase 2 Combination Study 1H ’20
The public float is only 2.98 million shares
INmune has no debt
Insiders own 63% of the outstanding shares and they continue to buy shares
Let’s just let the focus of INMB sink in. They are developing new immunotherapies to empower the body’s innate immune system to target and fight back against some of the world’s most debilitating conditions.
INMB shares are trading over 40% below the analysts target price and their 52-week high.
We urge you to investigate and do your due diligence on INMB. Their website https://www.inmunebio.com/index.php/en/ is filled with technical data and presentations that are in more detail than will fit in our newsletter. We will continue to review the company’s valuation with you and the potential for that valuation to grow.
We think you may find this company to be as remarkable and exciting as we do.
Our Full report on INmune Bio (NASDAQ: INMB) – http://tradersnewssource.com/inmune-bio/#
TradersNewsSource.com collects your contact information to keep you informed about updates to our web site, newsletters and social channels. All information is kept secure, with only authorized employees having access.
TradersNewsSource.com does from time to time, issue releases to subscribers as “Feature Reports” that may be related to our content partners or advertising sponsors.
We do not sell your contact information to other organizations for commercial purposes. We will not release your email address to anyone, unless you specifically give us permission to do so. Should you decide in the future to unsubscribe from TradersNewsSource.com at any time, simply follow the instructions located at the bottom of each newsletter edition. Your email address will be kept strictly confidential, and will never be shared with anyone for any purpose of any kind.
Regarding Google ads:
ALL STOCKS INVOLVE RISKS AND THE POSSIBILITY OF LOSING ALL OF YOUR INVESTMENT. PLEASE CONSIDER ALL RISKS BEFORE INVESTING.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. TNS LLC’s parent company has been compensated fifty thousand dollars cash via bank wire by invictus resources for a ninety day term of investor relations and awareness of INMB starting on 7/19/19. TNS LLC’s operators do not hold any form of equity in INMB. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.